Don Stevens - Hematology and Medical Oncology, Norton Cancer Institute

基本信息

浏览量：53

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 135 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab in Patients with Treatment-Naive or Relapsed / Refractory Mantle Cell Lymphoma: Phase Ib Trial

Tycel Phillips,Michael Wang,Tadeusz Robak,David Gallinson,Don Stevens,Krish Patel,Safaa Ramadan,Chuan-Chuan Wun,Wojciech Jurczak,Stephen D Smith

Haematologicano. 3 (2025): 715-724

引用0浏览0WOS引用

Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Experience from the ALPHA2/ALPHA Clinical Studies

Frederick L Locke,Javier L Munoz,Michael T Tees,Lazaros J Lekakis,Sven de Vos,Rajneesh Nath,Don A Stevens,Shahbaz A Malik,Geoffrey P Shouse,Mehdi Hamadani,Olalekan O Oluwole,Miguel-Angel Perales,David B Miklos, Paul W Fisher,Amy Feng,Lynn Navale, John B Le Gall,Sattva S Neelapu

Journal of clinical oncology official journal of the American Society of Clinical Oncologypp.101200JCO2401933-101200JCO2401933, (2025)

引用0浏览0WOS引用

Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Advanced Splicing Factor-Mutant Myeloid Malignancies

Jan Philipp Bewersdorf,Xiaoli Mi,Bin Lu,Andrew Kuykendall,David Sallman,Manish Patel,Don Stevens, Alexander Philipovskiy,Grerk Sutamtewagul,Lucia Masarova,Gina Keiffer,Amit Verma,Neha Bhagwat,Min Wang, Andrew Moore,Joseph Rager,Diane Heiser,Sunhee Ro, Wan-Jen Hong,Omar Abdel-Wahab,Eytan M. Stein

Leukemiapp.1-5, (2025)

引用0浏览0WOSNATURE引用

WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Amanda F. Cashen, MHD Monzr M. Al Malki,Don A. Stevens,Lori Muffly,Natasha Edwin,Edward Abadir,Peter Tan, Sandrine Niyongere,Ashish Bajel,Laura Arthur,Nitin Mahajan, Ben Capoccia,Tom Leedom, Basia Muz,Kristann Magee,Ouiam Bakkacha, Justo L. Gonzalez, Deborah Masters, Stephen Moran,Eileen McNulty,Angela Pannunzio,Jayakumar Vadakekolathu, Tony Wu, Maria del Rosario, Preeta Dasgupta, Michael Munroe, Laura Simpson,Melissa M Berrien-Elliott,John Muth,Sergio Rutella,Jan K Davidson-Moncada,Todd A Fehniger

Bloodno. Supplement 1 (2024): 4257-4257

引用0浏览0引用

A Phase 1/2 Clinical Trial of Invariant Natural Killer T Cell Therapy in Moderate-Severe Acute Respiratory Distress Syndrome

Terese C. Hammond,Marco A. Purbhoo,Sapana Kadel,Jerome Ritz,Sarah Nikiforow,Heather Daley,Kit Shaw,Koen van Besien,Alexandra Gomez-Arteaga,Don Stevens, Waldo Ortuzar,Xavier Michelet,Rachel Smith,Darrian Moskowitz,Reed Masakayan,Burcu Yigit,Shannon Boi,Kah Teong Soh, John Chamberland, Xin Song, Yu Qin, Ilya Mishchenko, Maurice Kirby, Valeriia Nasonenko,Alexa Buffa,Jennifer S. Buell,Dhan Chand,Marc van Dijk,Justin Stebbing,Mark A. Exley

NATURE COMMUNICATIONSno. 1 (2024)

引用1浏览0WOSNATURE引用

CT-419 ALPHA2: A Phase 1b Study Evaluating the CD19 Allogeneic CAR T Cell Product Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

David Miklos,Sushma Bharadwaj,Houston Holmes,Olalekan Oluwole, Andrew Jallouk,Sattva Neelapu,Nitin Jain, Rajneesh Nath,Javier Munoz,Locke Bryan,Sven De Vos,Herbert Eradat, Rushang Patel,Michael Tees, Stephanie Tsai,Kirk Cahill, Melhem Sohl,Geoffrey Shouse,Don Stevens, Paul Fisher

Clinical Lymphoma Myeloma and Leukemia (2024): S604

引用0浏览0引用

ALPHA2: A Phase 1b Study Evaluating the CD19 Allogeneic CAR T Cell Product Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Relapsed/ Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2024): S604-S604

引用0浏览0引用

Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T-Naive and CAR-T-Exposed Patients

Sameh Gaballa,Jing-Zhou Hou,Sumana Devata,Seok-Goo Cho,Ranjit Nair,Dok Hyun Yoon, Ryan Jacobs, Koji Izutsu,Don A. Stevens,Dai Maruyama,Constantine S. Tam,Yazeed Sawalha,Aravind Ramakrishnan,Matthew Matasar, Denise Brennan, Sue Zhu, Robin Lesley, Yasuhiro Oki,David Sermer, Tae Min Kim

Bloodno. Supplement 1 (2024): 868-868

引用0浏览0引用

ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First-Line (1L) Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) after Response to Standard Therapy

Jason Westin, John Burke,Ryan Lynch,Jeremy Abramson,Don Stevens,Matthew Matasar,Lindsey Fitzgerald, Alan Zausner Skarbnik,Chaitanya Iragavarapu,James Essell,Bradley Hunter,Akil Merchant,Indumathy Varadarajan,Anand Tandra,Edward Licitra,Locke Bryan,Rushang D. Patel, Rajesh Behl, Jeff Sharmann, Houston E. Holmes,Suzanne Fanning,Habte Yimer,Mitul Gandhi,Gary Simmons,Amy Feng,Lynn Navale, Srinivas Ghatta, John B. Le Gall,Alex F. Herrera

Clinical Lymphoma Myeloma and Leukemia (2024): S251

引用0浏览0引用

A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma

Swaminathan P Iyer,Ranjit Nair,Neha Mehta-Shah,Don A. Stevens,Alessandra Tucci,Antonio Pinto,Pier Luigi Zinzani

Bloodno. Supplement 1 (2024): 4449-4449

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn